Harnessing the parathyroid hormone, Wnt, and bone morphogenetic protein signaling cascades for successful bone tissue engineering

Tissue Engineering - Part B: Reviews

Volumn 17, Issue 6, 2011, Pages 475-479

  Rosen, Vicki ^a  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVE MOLECULES; BONE FORMATION; BONE MORPHOGENETIC PROTEINS; BONE REPAIR; BONE TISSUE; BONE TISSUE ENGINEERING; CLINICAL SITUATIONS; EXTRACELLULAR MATRICES; PARATHYROID HORMONES; REPARATIVE RESPONSE; SIGNALING CASCADES;

CELLS; ENZYME INHIBITION; PROTEINS; TISSUE; TISSUE ENGINEERING;

BONE;

BONE MORPHOGENETIC PROTEIN; PARATHYROID HORMONE; WNT PROTEIN;

BONE REGENERATION; BONE REMODELING; BONE TISSUE; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TISSUE ENGINEERING;

ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; HUMANS; PARATHYROID HORMONE; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; WNT PROTEINS;

EID: 81755188432     PISSN: 19373368     EISSN: 19373376     Source Type: Journal    
DOI: 10.1089/ten.teb.2011.0265     Document Type: Review

References (50)

1. Kawaguchi, H., Oka, H., Jingushi, S., Izumi, T., Fukunaga, M., Sato, K., Matsushita, T., Nakamura, K; and TESK Group. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: a randomized placebocontrolled trial. J Bone Miner Res 25, 2735, 2010.
2. Kawaguchi, H., Nakamura, K., Tabata, Y., Ikada, Y., Aoyama, I., Anzai, J., Nakamura, T., Hiyama, Y., and Tamura, M. Acceleration of fracture healing in nonhuman primates by FGF-2. J Clin Endocrinol Metab. 86, 875, 2001.
3. Komatsu, D.E., Mary, M.N., Schroeder, R.J., Robling, A.G., Turner, C.T., and Warder, S.J. Modulation of Wnt signaling influences fracture repair. J Orthop Res 28, 928, 2010.
4. Gaur, T., Wixted, J.J., Hussain, S., O'Connell, S.L., Morgan, E.F., Ayers, D.C., Komm, B.S., Bodine, P.V., Stein, G.S., and Lian, J.B. Secreted frizzled related protein 1 is a target to improve fracture healing. J Cell Physiol 220, 174, 2009.
5. Wang, Q., Huang, C., Zeng, F., Xue, M., and Zhang, X. Activation of the Hh pathway in periosteum-derived mesenchymal stem cells induces bone formation in vivo. Am J Pathol 177, 3100, 2010.
6. Srouji, S., Blumenfeld, I., Rachmiel, A., and Livne, E. Bone defect repair in rat tibia by TGFb and IGF1 released from hydrogel scaffold. Cell Tissue Bank 5, 223, 2004.
7. Schmidmaier, G., Wildemann, B., Ostapowicz, D., Kandziora, F., Stange, R., Haas, N.P., and Raschke, M. Long-term effects of local growth factor (IGF-1 and TGFb1) treatment on fracture healing. A safety study for using growth factors. J Orthop Res 22, 514, 2004.
8. Graham, S., Leonidou, A., Lester, M., Heliotos, M., Mantalaris, A., and Tsiridis, E. Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing. Expert Opin Investig Drugs 18, 1633, 2009.
9. Hollinger, J.O., Hart, C.E., Hirsch, S.N., Lynch, S., and Friedlaender, G.E. Recombinant human PDGF: biology and clinical applications. J Bone Joint Surg Am 90, 48, 2008.
10. Fu, L., Tang, T., Miao, Y., Hao, Y., and Dai, K. Effect of 1,25-dihydroxy vitamin D3 on fracture healing and bone remodeling in ovariectomized rat femora. Bone 44, 893, 2009.
11. Naik, A.A., Xie, C., Zuscik, M.J., Kingsley, P., Schwarz, E.M., Awad, H., Guldberg, R., Drissi, H., Puzas, E., Boyce, B., Zhang, X., and O'Keefe, R.J. Reduced Cox-2 expression in aged mice is associated with impaired fracture healing. J Bone Miner Res 24, 251, 2009.
12. Zhang, M., Ho, H.-C., Sheu, T.-J., Breyer, M.D., Flick, L.M., Jonason, J.H., Awad, H.A., Schwarz, E.M., and O'Keefe, R.J. EP-/-mice have enhanced osteoblast differentiation and accelerated fracture repair. J Bone Miner Res 26, 792, 2011.
13. Uusitalo, H., Hiltunen, A., Ahonen, M., Kahari, V.-M., Aro, H., and Vuorio, E. Induction of periosteal callus formation by BMP2 employing adenovirus-mediated gene delivery. Matrix Biol 20, 123, 2001.
14. Xie, C., Reynolds, D., Awad, H., Rubery, P.T., Pelled, G., Gazit, D., Guldberg, R.E., Schwarz, E.M., O'Keefe, R.J., and Zhang, X. Structural bone allograft combined with genetically engineered mesenchymal stem cells as a novel platform for bone tissue engineering. Tissue Eng 13, 435, 2007.
15. Reynolds, D.G., Takahata, M., Lerner, A.L., O'Keefe, R.J., Schwarz, E.M., and Awad, H.A. Teripeptide therapy enhances devitalized femoral allograft osseointegration and biomechanics in a murine model. Bone 48, 562, 2011.
16. Lane, N.E., and Silverman, S.L. Anabolic therapies. Curr Osteoporos Rep 8, 23, 2010.
17. Kakar, S., Einhorn, T.A., Vora, S., Miara, L.J., Hon, G., Wigner, N.A., Toben, D., Jacobsen, K.A., Al-Sebaei, M.O., Song, M., Trackman, P.C., Morgan, E.F., Gerstenfeld, L.C., and Barnes, G.L. Enhanced chondrogenesis and wnt signaling in PTH-treated fractures. J Bone Miner Res 22, 1903, 2007.
18. Rowshan, H.H., Parham, M.A., Baur, D.A., McEntee, R.D., Caley, E., Carriere, D.T., Wood, J.C., Demsar, W.J., and Pizarro, J.M. Effect of intermittent systemic administration of recombinant parathyroid hormone (1-34) on mandibular fracture healing in rats. J Oral Maxillofac Surg 68, 260, 2010.
19. O'Loughlin, P.F., Cunningham, M.E., Bukata, S.V., Tomin, E., Poynton, A.R., Doty, S.B., Sama, A.A., and Lane, J.M. Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine 34, 121, 2009.
20. Sloan, A.V., Martin, J.R., Li, S., and Li, J. Parathyroid hormone and bisphosphonates have opposite effects on stress fracture repair. Bone 47, 235, 2010.
21. Takahata, M., Awad, H.A., O'Keefe, R.J., Bukata, S.V., and Schwarz, E.M. Endogenous tissue engineering: PTH therapy for skeletal repair. Cell Tissue Res 31 May 2011 [Epub ahead of print]; DOI: 10.1007/S00441-011-1188-4.
22. Taqil, M., McDonald, M.M., Morse, A., Peacock, L., Mikulec, K., Amanat, N., Godfrey, C., and Little, D.G. Intermittent PTH (1-34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures. Bone 46, 852, 2010.
23. Ogita, M., Rached, M.T., Dworakowski, E., Bilezikian, J.P., and Kousteni, S. Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent PTH administration. Endocrinology 149, 5713, 2008.
24. Jilka, R.L., O'Brien, C.A., Ali, A.A., Roberson, P.K., Weinstein, R.S., and Manolagas, S.C. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 44, 275, 2009.
25. Drake, M.T., Srinivasan, B., Modder, U.I., Peterson, J.M., McCready, L.K., Riggs, B.L., Dwyer, D., Stolina, M., Kostenuik, P., and Khosla, S. Effects of PTH treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95, 5056, 2010.
26. Kramer, I., Keller, H., Leupin, O., and Kneissel, M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metabol 21, 237, 2010.
27. Padhi, D., Jang, G., Stouch, B., Fang, L., and Posvar, E. Single-dose, placebo controlled randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26, 19, 2011.
28. Macsai, C.E., Foster, B.K., and Xian, C.J. Roles of Wnt signaling in bone growth, remodeling, skeletal disorders and fracture repair. J Cell Physiol 215, 578, 2008.
29. Bajada, S., Marshall, M.J., Wright, K.T., Richardson, J.B., and Johnson, W.E.B. Decreased osteogenesis, increased cell senescence and elevated Dickkopf-1 secretion in human fracture non union stromal cells. Bone 45, 726, 2009.
30. Ominsky, M.S., Li, C., Li, X., Tan, H.L., Lee, E., Barrero, M., Asuncion, F.J., Dwyer, D., Han, C.-Y., Vlasseros, F., Samadfam, R., Jolette, J., Smith, S.Y., Stolina, M., Lacey, D.L., Simonet, W.S., Paszty, C., Li, G., and Ke, H.Z. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26, 1012, 2011.
31. Chen, Y., Whetstone, H.C., Lin, A.C., Nadesan, P., Wei, Q., Poon, R., and Alman, B.A. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med 4, 1216, 2007.
32. Quarto, N., Behr, B., and Longaker, M.T. Opposite spectrum of activity of canonical wnt signaling in the osteogenic context of undifferentiated and differentiated mesenchymal cells: implications for tissue engineering. Tissue Eng Part A 16, 3185, 2010.
33. Fleming, H.E., Janzen, V., LoCleso, C., Gua, J., Leahy, K.M., Kronenberg, H.M., and Scadden, D.T. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2, 274, 2008.
34. Caetano-Lopes, J., Lopes, A., Rodrigues, A., Fernandes, D., Perpetuo, I.P., Monjardino, T., Lucas, R., Monteiro, J., Konttinen, Y.T., Canhao, H., and Fonseca, J.E. Up-regulation of inflammatory genes and downregulation of sclerostin gene expression are key elements in the early phase of fragility fracture healing. PLoS One 6, e16947, 2011.
35. Lowery, W., and de Caestecker, M.P. BMP signaling in vascular development and disease. Cytokine Growth Factor Rev 21, 287, 2010.
36. Rosen, V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci 1068, 19, 2006.
37. Daluiski, A., Engstrand, T., Bahamonde, M.E., Gamer, L.W., Agius, E., Stevenson, S.L., Cox, K., Rosen, V., and Lyons, K.M. Bone morphogenetic protein 3 is a negative regulator of bone density. Nat Genet 27, 84, 2001.
38. Rosen, V. BMP2 signaling in bone development and repair. Cytokine Growth Factor Rev 20, 475, 2009.
39. Tsuji, K., Bandyopadhyay, A., Harfe, B.D., Cox, K., Kakar, S., Gerstenfeld, L., Einhorn, T., Tabin, C.J., and Rosen, V. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 38, 1424, 2006.
40. Yu, Y.Y., Lieu, S., Lu, C., and Colnot, C. Bone morphogenetic protein 2 stimulates endochondral ossification by regulating periosteal cell fate during bone repair. Bone 47, 65, 2010.
41. Murnaghan, M., McIlmurray, L., Mushipe, M.T., and Li, G. Time for treating bone fracture using rhBMP-2: a randomized placebo controlled mouse fracture trial. J Orthop Res 23, 625, 2005.
42. Yu, P.B., Deng, D.Y., Lai, C.S., Hong, C.C., Cuny, G.D., Bouxsein, M.L., Hong, D.W., McManus, P.M., Katagiri, T., Sachidanandan, C., Kamiya, N., Fukida, T., Mishina, Y., Peterson, R.T., and Bloch, K.D. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med 14, 1363, 2008.
43. Cho, T.-J., Gerstenfeld, L.C., and Einhorn, T.A. Differential temporal expression of members of the transforming growth factor b superfamily during murine fracture healing. J Bone Miner Res 17, 513, 2002.
44. Kidd, L.J., Stephens, A.S., Kuliwaba, J.S., Fazzalari, N.L., Wu, A.C.K., and Forwood, M.R. Temporal pattern of gene expression and histology of stress fracture healing. Bone 46, 369, 2010.
45. Wang, M., Jin, H., Tang, D., Huang, S., Zuscik, M.J., and Chen, D. Smad 1 plays an essential role in bone development and postnatal bone formation. Osteoarthritis Cartilage 19, 751, 2011.
46. Takase, H., Yano, S., Yamaguichi, T., Kanazawa, I., Hayashi, K., Yamamoto, M., Yamauchi, M., and Sugimoto, T. Parathyroid hormone upregulates BMP-2 mRNA expression through mevalonate kinase and rho kinase inhibition in osteoblastic MC3T3-E1 cells. Horm Metab Res 41, 861, 2009.
47. Morgan, E.F., Mason, Z.D., Bishop, G., Davis, A.D., Wigner, N.A., Gerstenfeld, L.C., and Einhorn, T,A.Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1-34) in metaphyseal bone healing. Bone 43, 1031, 2008.
48. Kempen, D.H.R., Lu, L., Hefferan, T.E., Creemers, L.B., Heijink, A., Maran, A., Dhert, W.J.A., and Yaszemski, M.J. Enhanced bone morphogenetic protein-2-induced ectopic and orthotopic bone formation by intermittent parathyroid hormone (1-34) administration. Tissue Eng 16, 3769, 2010.
49. Drake, M.T., Srinivasan, B., Modder, U.I., Ng, A.C., Undale, A.H., Roforth, M.M., Peterson, J.M., McCready, L.K., Riggs, B.L., and Khosla, S. Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone 49, 349, 2011.
50. Lu, C., Miclau, T., Hu, D., Hansen, E., Tsui, K., Puttlitz, C., and Marcucio, R.S. Cellular basis for age-related changes in fracture repair. J Orthop Res 23, 1300, 2005.